Discounted Cash Flow (DCF) Analysis Levered
Vera Therapeutics, Inc. (VERA)
$7.76
+0.32 (+4.30%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2019 Projected | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | - | - | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | |||||||||
| Operating Cash Flow | - | - | - | - | - | - | - | - | - |
| Operating Cash Flow (%) | |||||||||
| Capital Expenditure | - | - | - | - | - | - | - | - | - |
| Capital Expenditure (%) | |||||||||
| Free Cash Flow | - | - | - | - | - | - | - | - | - |
Weighted Average Cost Of Capital
| Share price | $ 7.76 |
|---|---|
| Beta | 0.000 |
| Diluted Shares Outstanding | 26.57 |
| Cost of Debt | |
| Tax Rate | -0.00 |
| After-tax Cost of Debt | 3.17% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 3.494 |
| Total Debt | 31.29 |
| Total Equity | 206.19 |
| Total Capital | 237.47 |
| Debt Weighting | 13.17 |
| Equity Weighting | 86.83 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2019 Projected | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | - | - | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - | - | - | - |
| Capital Expenditure | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - |
| WACC | |||||||||
| PV LFCF | - | - | - | - | - | - | - | - | - |
| SUM PV LFCF | - |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 3.45 |
| Free cash flow (t + 1) | - |
| Terminal Value | - |
| Present Value of Terminal Value | - |
Intrinsic Value
| Enterprise Value | - |
|---|---|
| Net Debt | -12.17 |
| Equity Value | - |
| Shares Outstanding | 26.57 |
| Equity Value Per Share | - |